The trial will assess the safety and efficacy of the drug in Covid-19 patients. Credit: iXimus from Pixabay.

MGC Pharmaceuticals has started a Phase II clinical trial of ArtemiC for the treatment of patients suffering from Covid-19 infection.

First patients have been enroled at the Nazareth Hospital EMMS in Israel, with treatment scheduled to commence today.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Considered a food supplement, ArtemiC is designed to help address viral infections with inflammatory complications.

MGC said that available scientific data on Artemisinin and Curcumin properties supports the testing of ArtemiC in Covid-19 patients.

The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.

The aim is to treat the pathophysiological complications of Covid-19.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

MGC Pharmaceuticals will conduct the trial in a total of 50 patients at Israel’s Nazareth Hospital EMMS and Hillel Yaffe Hospital, which received human research ethics committee approval last month.

The trial is set to enrol new patients and will start treatment each week, with the study duration being 14 days per patient. Patient enrolment is expected to be completed in September 2020, with data made available in October.

Results will help validate ArtemiC, support design of future trials, and aid commercial discussions that are ongoing for the potential supply and sale of the drug.

The company will carry out research, manufacture and packaging for commercial orders from its operational facilities in Europe. It also has approval to start commercial production.

MGC Pharma co-founder and managing director Roby Zomer said: “This is a very exciting milestone for the company and the trial, and we look forward to updating our shareholders on results as they come to hand.”

The company will own the intellectual property generated from the clinical study.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact